Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1903624 | 1.00 | SPHK2 (0.48) | SPHK2SPHK1FAAHSLC6A4 | |
| SCHEMBL1257675 | 0.95 | SLC6A4 (0.49) | SPHK2SPHK1SLC6A4 | |
| SCHEMBL1257677 | 0.95 | SLC6A4 (0.49) | SPHK2SPHK1SLC6A4 | |
| SCHEMBL17154964 | 0.90 | GBA1 (0.44) | — | |
| SCHEMBL8414528 | 0.85 | SLC6A4 (0.48) | SPHK2SPHK1FAAHSLC6A4 | |
| SCHEMBL22287239 | 0.82 | MAPT (0.42) | — | |
| SCHEMBL8686933 | 0.81 | SLC6A4 (0.53) | SLC6A4 | |
| SCHEMBL5530480 | 0.80 | — | — | |
| SCHEMBL2997593 | 0.80 | — | — | |
| SCHEMBL1902756 | 0.80 | FAAH (0.53) | SPHK2SPHK1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140904-B1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6800636-B2 | FOR THERAPY OF CANCER | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
| EP-0912512-B1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | GUZI TIMOTHY (US) | 2003-02-27 | — | — | US | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
| US-6265408-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANT | SMITHKLINE BEECHAM PLC (GB) | 2001-07-24 | — | — | US | disclosed |
| EP-0912512-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048681-A1 | SULPHONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | FNTA, FNTB, CETP | SPHK2 2059/4885SPHK1 1685/4885FAAH 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.